This trial is testing if it is safe to give two different doses of a person's own bone marrow cells to treat lower extremity injuries complicated by compartment syndrome.
2 Primary · 13 Secondary · Reporting Duration: 6 weeks, 3 months, 6 months, and 12 months
Active Control
Experimental Treatment
18 Total Participants · 3 Treatment Groups
Primary Treatment: Intramuscular administration of autologous BM-MNCs · No Placebo Group · Phase 1
Age 18 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
Oregon Health & Science University | 100.0% |
Met criteria | 100.0% |
100.0% | |